A new pharmaceutical intended for persons with type 2 diabetes and with heart disease will be compensated in the amount of 50% from the mandatory health insurance funds, as the Council for Compensated Medicines decided. This is the medicine with the common international name dapagliflozin, IPN reports.
The Ministry of Health said dapagliflozin belongs to a new class of medical drugs that contain specific inhibitors used to treat diabetes. It is also recommended by the Ministry’s Endocrinology Commission for treating persons who have type 2 diabetes and simultaneously heart failure.
The National Health Insurance Company estimated that about 10,000 patients with chronic diseases will benefit from dapagliflozinum. A sum of 40 million lei will be allocated yearly from the mandatory health insurance funds for covering half of its price.
The Council for Compensated Medicines also announced that it completed the assessment of the files for the inclusion of another 11 common international names of medical drugs in the list of compensated drugs. A relevant decision will be taken after the National Health Insurance Company negotiates the producer prices with economic operators so as to cover the incurred costs from the mandatory health insurance funds.
